Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
2021 objectives leverage positive momentum in Arbutus’ Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a more...
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors SITC presentation from ongoing ADXS-503 Phase 1/2 clinical trial demonstrated disease control rate of 67% more...
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market PR Newswire CRANFORD, N.J. , Jan. 25, 2021 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and more...
2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fortress Biotech, Inc. (“Fortress” or “the Company”) more...
FBIO Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021
NEW YORK, NY / ACCESSWIRE / January 24, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. (“Fortress Biotech” or “the Company”) (NASDAQ:FBIO) more...
3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 23, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fortress Biotech, Inc. (“Fortress” or “the Company”) more...
FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action – FBIO
FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class Action – FBIO PR Newswire NEW YORK , Jan. 23, 2021 /PRNewswire/ — Rosen Law Firm, more...
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter PR Newswire TEL AVIV, Israel , Jan. 22, 2021 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), more...
JANUARY 26 FINAL DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 22, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fortress Biotech, Inc. (“Fortress” or “the Company”) more...
AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study
AzurRx BioPharma, Inc. AZRX announced that it has initiated dosing in the phase IIb OPTION 2 extension study evaluating MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with more...